左氧氟沙星与头孢哌酮/舒巴坦治疗社区获得性下呼吸道感染的对照研究

Levofloxacin and cefoperazone/sulbactam in the treatment of community-acquired lower respiratory tract bacterial infections:A randomized controlled clinical trial

目的探讨左氧氟沙星和头孢哌酮/舒巴坦治疗社区获得性下呼吸道感染的疗效及费用。方法采用前瞻开放性随机对照研究方法。选取符合社区获得性下呼吸道感染的病例180例,随机进入实验组和对照组各90例,实验组给予左氧氟沙星注射液(300mg/100ml)静脉滴注,每日1次,疗程5～14d;对照组给予头孢哌酮/舒巴坦(4g)静脉滴注,每日1次,疗程5～14d。结果实验组和对照组痊愈率分别为74.4%和78.9%;总有效率分别为92.2%和93.3%,两组痊愈率和有效率差异无显著性(P>0.05)。实验组细菌清除率和阴转率均为89.7%,对照组细菌清除率和阴转率均为90.0%,两组比较无统计学差别(P>0.05)。实验组平均疗程为(8.7±2.1)d,与对照组疗程(8.2±2.3)d比较,没有统计学差别(P>0.05)。两组不良反应发生率也无统计学意义,但医疗费用实验组(387.2±93.5)元,远低于对照组(615±172.5)元,具有统计学意义(P<0.05)。结论左氧氟沙星与头孢哌酮/舒巴坦具有相同的疗效,且医疗费用低,是治疗社区获得性下呼吸道感染安全有效的药物。

Objective To investigate the efficacy and cost of levofloxacin and cefoperazone/sulbactam in the treatment of community-acquired lower respiratory tract bacterial infections. Method A total of 180 cases with community-acquired lower respiratory tract bacterial infections were studied. A prospective randomized controlled clinical trial was conducted, and 0.3g levofloxacin or 4.0g cefoperazone/sulbactam as control were given by intravenous drip once a day for 7 to 14 days. Result The clinical efficacy rate of levofloxacin and cefoperazone/sulbactam were 92.2% and 93.3%; cure rate were 74.4% and 78.9%, and bacterial clearance were 89.7% and 90.0%, respectively. The courses of treatment were （8.7±2. 1）d in patients receiving levofloxacin, while （8.2±2. 3）d of control group. There was no statistical difference between two groups. The cost （RMB） of levofloxacin was significantly lower than that of cefoperazone/sulbactam （387.2±93. 5 vs 615± 172.5, P〈0.05）. Conclusion Levofloxacin therapy was as effective as cefoperazone/sulbactam in the treatment of community-acquired lower respiratory tract bacterial infections, but the cost （RMB） of levofloxacin was lower than that of cefoperazone/sulbactam.